Yu-Hao Huang¹, Yu-Ci Tu¹, Peng-Ju Chien^1,2, An-Jie Lee¹, Chia-Liang Lin³, Shao-Ti Li⁴, Yueh-Chun Lee^4,5,*, Wen-Wei Chang^1,6,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.075190 - 22 April 2026

Abstract Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and resistance to conventional therapies, including radiotherapy. Cancer stem cells (CSCs) drive tumor initiation, metastasis, and therapy resistance in TNBC. Identifying pathways sustaining CSCs in radioresistant TNBC is key for targeted therapies. This study examines SRC proto-oncogene (SRC) and the signal transducer and activator of transcription 3 (STAT3) activation in radioresistance and CSC maintenance. Methods: A radioresistant MDA-MB-231 TNBC cell line (231RR) was developed and compared to the parental line for CSC activity and self-renewal. Western blotting assessed molecular changes; functional assays followed… More >

Evangelos Manousakis¹, Cristina Moreta-Moraleda¹, Clàudia Martinez Miralles¹, Anna Tomàs Pujolà¹, Houda Baccara², Laia Liñán Franquet¹, Montserrat Montañés Albó¹, Roberto Ferrari², Roni H. G. Wright^1,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.074965 - 22 April 2026

Abstract Objective: Breast cancer remains one of the most prevalent malignancies among women worldwide, and despite advances in therapy and treatment options, tumour relapse and metastasis remain major clinical challenges, largely driven by the breast cancer stem cells (BCSCs) niche that resists conventional treatments and regenerates tumours. In breast cancer, where approximately 30% of patients who initially respond to treatment ultimately relapse and die of metastatic disease, targeting BCSCs is critical for improving patient outcomes. Cyclin-dependent kinase inhibitor 1A/p21 (CDKN1A/p21) is a multifunctional protein that is known primarily for its role in regulating the cell cycle… More > Graphic Abstract

Myeong Ryeo Kim^1,*, Jae Rim Lee¹, Xiaohan Zhang², Kwang Won Jeong^1,*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.072592 - 24 February 2026

Abstract Objectives: Tamoxifen is a key drug that provides endocrine therapy for estrogen receptor (ER) α-positive breast cancer; however, resistance remains a significant clinical challenge. This study aims to investigate the molecular mechanisms of tamoxifen resistance in ERα-positive breast cancer, with particular focus on the role of SET Domain Containing 1A (SETD1A)-driven forkhead box A2 (FOXA2) as a key regulator of this resistance. Methods: FOXA2 expression and its regulation by SETD1A were assessed via (quantitative polymerase chain reaction), western blotting, transcriptome profiling, and chromatin immunoprecipitation analyses. The effects of FOXA2 on cell proliferation, migration, invasion, and cancer… More >

Oncology Research Editorial Office

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.077268 - 30 December 2025

Abstract This article has no abstract. More >

Fangyuan Li^1,2,#, Xiaoyuan Hu^1,#, Xiaoge Gao³, Ling Liu³, Tao Li¹, Dan He¹, Jiaxing Cheng¹, Xiaobiao Ma¹, Li Li^1,*, Chunlei Ge^1,*, Hong Yao^1,*

Oncology Research, Vol.33, No.12, pp. 4029-4048, 2025, DOI:10.32604/or.2025.067628 - 27 November 2025

Abstract Background: Liver cancer stem cells (LCSCs) are recognized as pivotal drivers of hepatocellular carcinoma (HCC) progression; however, the molecular mechanisms maintaining their stem-like phenotype remain largely unresolved. This work investigates the role of prefoldin subunit 6-like protein (PFDN6L) in shaping LCSC traits and promoting or restraining HCC progression. Methods: PFDN6L, a cytoskeleton-associated chaperone, was studied using multiple in vitro assays—cell growth evaluation, cell cycle profiling, and spheroid culture—alongside analyses of stemness-associated markers (SOX2, CD133, CD44). Tumorigenic capacity was assessed in xenograft mouse models, and signaling pathway interrogation was performed to define underlying mechanisms. Results: In patient samples, More >

Sotirios Charalampos Diamantoudis^1,#,*, Androulla N. Miliotou^2,#, Eleftheria Galatou², Stergiani Telliou³, Konstantinos Sideris⁴, Nikolaos Grigoriadis¹, Ioannis S. Vizirianakis^1,2,*

BIOCELL, Vol.49, No.10, pp. 1799-1858, 2025, DOI:10.32604/biocell.2025.067216 - 22 October 2025

Abstract Hematological cancer stem cells (HCSCs) is a subpopulation of cells within hematological cancers that, through their characteristics, enhance malignancy and render their therapy more challenging. By uncovering the underlying mechanisms behind characteristic properties such as self-renewal, immune evasion, and conventional therapy resistance, as well as the major differences between other cancers and physiological cells, new and alternative targets can be assessed for use in existing and novel immunotherapeutic interventions. Through the evaluation of the existing literature, one can realize that there have already been several studies addressing the use of stem cell transplantation (SCT), monoclonal More > Graphic Abstract

Alejandro Javier Español^1,2,*, Yamila Sanchez¹, Sofia Volpi²

BIOCELL, Vol.49, No.8, pp. 1449-1480, 2025, DOI:10.32604/biocell.2025.068034 - 29 August 2025

Abstract Background: Triple-negative (TN) breast cancer, the most aggressive subtype of breast cancer, is usually treated with high doses of paclitaxel (PX), which induces resistance. To prevent this adverse effect, metronomic chemotherapy based on administering low doses of PX plus carbachol (Carb), a muscarinic acetylcholine receptor (mAChR) agonist, has emerged as an alternative. Other acetylcholine receptors also present in breast tissue are nicotinic ones. When activated by nicotine (Nic), these receptors can decrease the effectiveness of conventional chemotherapy. However, whether metronomic chemotherapy with PX and Carb is affected by Nic has not yet been described. This… More >

Dmitriy Vladimirovich Karpenko^*

BIOCELL, Vol.49, No.5, pp. 743-765, 2025, DOI:10.32604/biocell.2025.062791 - 27 May 2025

Abstract Cancer is a highly heterogeneous pathology that poses a significant threat to millions of lives worldwide. In recent decades, there has been a substantial advancement in our understanding of the mechanisms underlying oncogenesis. Contemporary models now take into account the intricate interplay between cancer cells, immune cells, and other non-pathological cells during oncogenesis. The identification of small subpopulations of cancer stem cells has emerged as a crucial area of research, as these cells have been associated with cancer progression and resistance to various therapeutic interventions. The ability to distinguish between cancer stem cells and non-pathological… More >

Qing Wang, Luyao Cai, Shouyi Tang, Dan Pan, Zhen Wang, Qianming Chen, Yu Zhou^*, Yingqiang Shen^*

BIOCELL, Vol.49, No.4, pp. 579-605, 2025, DOI:10.32604/biocell.2025.060045 - 30 April 2025

Abstract Cancer Stem Cells (CSCs) are cancer cells with self-renewal and tumorigenesis abilities. CSCs in tumor tissues are the leading cause of tumor progression, recurrence, and drug resistance. CSCs have distinct metabolic features that contribute to maintaining their self-renewal and stemness. Phospholipids are essential components of cell membranes and play fundamental roles in cellular activities. CSCs have abnormal phospholipid metabolism, which affects their self-renewal, differentiation, invasion, and drug resistance. Compared with non-CSCs, the phospholipid metabolism of CSCs mainly focused on significantly increased fatty acid (FAs) and phospholipids synthesis, phospholipid unsaturation, and lipolysis-fatty acid oxidation (FAO). In More > Graphic Abstract

MOEKA NAKASHIMA, NAOKO SUGA, AKARI FUKUMOTO, SAYURI YOSHIKAWA, SATORU MATSUDA^*

Oncology Research, Vol.33, No.5, pp. 1007-1017, 2025, DOI:10.32604/or.2025.059657 - 18 April 2025

Abstract Malignant tumors are heterogeneous diseases characterized by uncontrolled cell proliferation, invasion, metastasis, and/or recurrence of their malignancies. In particular, cancer stem cells (CSCs) within these tumors might be responsible for the property of invasiveness and/or therapies-resistance. CSCs are a self-renewing, awfully tumorigenic subpopulation of cancer cells, which are notorious for strong chemoresistance and are frequently responsible the aggravated invasion, metastasis, and/or recurrence. Developing targeting therapies against CSCs, therefore, may be deliberated a more encouraging mission for the greater cancer therapy. Innovation for a more potent anti-CSC treatment has been required as soon as possible.… More > Graphic Abstract